Top Injectable Manufacturer in Cyprus – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 4 hours ago
- 7 min read
Last Updated: September 6, 2026
TL;DR: Cyprus is an EU member state, and that makes it a different animal from every market this series has covered. The question is not whether India is on a reference list — there is no such list to be on. It is who holds the marketing authorisation and who certifies the site. The EU's published mutual recognition partners for GMP are Australia, Canada, Israel, Japan, New Zealand, Switzerland and the United States; India is not among them. Article 8(2) of Directive 2001/83/EC, in the consolidated text as at 1 January 2025, provides that a marketing authorisation may only be granted to an applicant established in the Community.
Key Takeaways
We found no reliance route, and nothing we read in the trade agreement creates one. The EU's published MRA partners on GMP are Australia, Canada, Israel, Japan, New Zealand, Switzerland and the United States. India does not appear on the European Commission's list of third countries assessed as having an equivalent framework for active substances. The EU and India concluded free-trade negotiations on 27 January 2026, and the Commission's published chapter-by-chapter summary shows no chapter or annex providing for mutual recognition of GMP inspections.
Two regulatory objects, not one. The marketing authorisation licenses a product, in a form and strength; in Cyprus it is granted by the Drugs Council on the Pharmaceutical Services' assessment, on a CTD dossier filed in eCTD. The manufacturing authorisation licenses a named legal person to make or import named products at named premises, is granted after inspection, and requires a qualified person permanently and continuously. A site outside the EEA receives instead an EU GMP certificate, recorded in EudraGMDP.
Importing means an EU authorisation, a Qualified Person and, for India, importation testing. The Pharmaceutical Services' own page states that the manufacturing authorisation is also required for imports of medicinal products originating in third countries. Under Article 51(2) of Directive 2001/83/EC a qualified person is relieved of importation controls only where they were carried out in a third country with which the EU has an MRA — and no EU–India MRA exists.
A small, price-disciplined market with a manufacturing base of its own. Cyprus sets maximum wholesale prices by external reference pricing against a basket of ten European countries, with the first generic entering at 80% of the originator's maximum wholesale price. Retail pharmaceutical spending was 467 euro per capita (PPP-adjusted) in 2023 against an EU average of 510.
Introduction: Why Cyprus Demands a Premium Injectable Manufacturer in Cyprus
Every market in this series opens with the same question — does the country name the regulators it will lean on, and is India's CDSCO among them — and Cyprus is the first where the question itself has to be rewritten. Cyprus is an EU member state. Medicines are authorised under Directive 2001/83/EC and Regulation (EC) No 726/2004, and there is no national reference list on which an Indian approval might or might not appear. What exists instead is structural, and is better described by two questions: who holds the marketing authorisation, and who certifies the manufacturing site?
On the first, Article 8(2) of the Directive, which we read in the consolidated text as at 1 January 2025, provides that a marketing authorisation may only be granted to an applicant established in the Community. On the second, the EU's published mutual recognition partners for GMP are Australia, Canada, Israel, Japan, New Zealand, Switzerland and the United States; India is not among them, and India does not appear on the Commission's list of third countries with an equivalent framework for active substances; CDSCO still issues the written confirmations for active substances that only unlisted countries need to issue. No shortcut is arriving: the EU and India concluded free-trade negotiations on 27 January 2026, and the Commission's published chapter-by-chapter summary shows no chapter or annex providing for mutual recognition of GMP inspections. A serious injectable manufacturer in Cyprus says all of that out loud.
What Sets a World-Class Injectable Manufacturer in Cyprus Apart
The cleanest primary evidence here is the Pharmaceutical Services' own page on manufacturing and import authorisations. Under Cypriot law, manufacture of medicinal products and operations of dividing up, packaging and presentation are permitted only under an authorisation granted by the Drugs Council — and the same page states that the authorisation is also required for imports of medicinal products originating in third countries into the Republic. It is granted only after inspection, requires at least one qualified person on a permanent and continuous basis, is issued within 90 days of a complete file, and runs five years. Somebody in the EEA must hold that authorisation, and that somebody cannot be an entity located in India.
Separating the site regime from the product regime is what makes an honest offer possible. A WHO-GMP certificate issued by an Indian state licensing authority is evidence about a site. It is not a marketing authorisation, and it is not an EU GMP certificate: the EU runs its own GMP guide, inspections and certification, and absent an MRA it does not treat WHO-GMP as a substitute. EU GMP certificates for third-country sites are issued following inspection by an EEA competent authority and recorded in EudraGMDP; we could not query that database successfully and make no claim about which Indian sites appear in it.
Quality Systems Behind Every Injectable Supplied to Cyprus
For a sterile injectable entering the EU the technical expectations are the EudraLex ones, and they are met at the line rather than in correspondence: aseptic process simulation for the ISO Class 5 filling operation, environmental monitoring with trended data, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, and validated HPLC and GC methods for assay and related substances. Module 3 of the CTD carries all of it, and Cyprus files in eCTD.
One further capability is worth building before it is asked for — serialisation: Delegated Regulation (EU) 2016/161 has applied since 9 February 2019 and requires a unique identifier and an anti-tampering device on the outer packaging, verified through the national system operated in Cyprus by KOEF, while the obligation to upload the identifier data sits with the authorisation holder. One legislative caution: Parliament and Council reached political agreement on reforming EU pharmaceutical legislation on 11 December 2025, but as of writing we have not verified formal adoption or Official Journal publication, and Directive 2001/83/EC and Regulation (EC) No 726/2004 remain the operative instruments.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Cyprus for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Cyprus the offer is deliberately narrower than the title of this article suggests: we are a contract manufacturer for partners who hold, or intend to hold, an EU marketing authorisation. The site is capable — WHO-GMP certified, and EU-GMP certified if and when an EEA competent authority inspects and certifies it. The product is authorised by someone else, and the batches are certified by someone else, because no MRA waiver applies to goods made in India.
What that leaves out matters as much as what it includes. We hold no Cypriot or EU marketing authorisation, we are not established in the EU, and no CDSCO approval advances a European application. We found no India–Cyprus health or pharmaceutical memorandum, which is not the same as saying none exists. India–Cyprus bilateral trade was approximately USD 140 million in 2024–25; we do not publish a disaggregated pharmaceutical figure, because the one we found came from a reseller we could not corroborate.
On procurement, the well-documented architecture is the pre-2019 one recorded by PPRI: central tendering, open invitations for off-patent products and negotiation for on-patent ones, with tenders above 133,000 euro published in the EU's Tenders Electronic Daily. GESY changed that architecture, and current arrangements should be confirmed with the Pharmaceutical Services and the Health Insurance Organisation rather than assumed. Our own count of pharmaceutical notices on Tenders Electronic Daily with Cyprus as the place of performance, retrieved on 6 September 2026, is approximately 3,085 — notice counts, not contract counts, and ours rather than official statistics. Population figures must carry their basis: about 966,365 on Eurostat's 2024 figure for the areas under the effective control of the Republic, against whole-island estimates of roughly 1.3 million.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Does Cyprus or the EU accept Indian CDSCO approvals?
No. Cyprus authorises medicines under EU law, and a CDSCO approval has no standing in a Cypriot or EU marketing authorisation procedure. The EU's published mutual recognition partners for GMP are Australia, Canada, Israel, Japan, New Zealand, Switzerland and the United States; India is not among them, and India does not appear on the Commission's list of third countries with an equivalent framework for active substances. India's WHO maturity level 3 listing carries the scope 'Vaccines (producing)'.
Can an Indian company hold a marketing authorisation in Cyprus?
Article 8(2) of Directive 2001/83/EC, in the consolidated text as at 1 January 2025, provides that a marketing authorisation may only be granted to an applicant established in the Community. In practice an Indian manufacturer works through an EU-established partner who holds the authorisation and names the Indian site in Module 3. A derogation inserted by Directive (EU) 2022/642 let Cyprus, Ireland and Malta grant certain authorisations to applicants established in parts of the United Kingdom outside Northern Ireland until 31 December 2024; those cease to be valid at the latest on 31 December 2026.
Is WHO-GMP certification enough to supply Cyprus?
No. WHO-GMP certification is evidence about a site, and useful evidence, but EU supply additionally requires EU GMP compliance verified by an inspection carried out by an EEA competent authority, recorded in EudraGMDP, and a marketing authorisation held by an EU-established holder. Because there is no EU–India mutual recognition agreement, the Article 51(2) waiver from importation controls does not apply, so importation testing is performed on each batch in the EU.
How are medicines priced and bought in Cyprus?
Maximum wholesale prices are set by external reference pricing against ten countries — Germany, Denmark and Austria in the high group, Italy, Belgium, Sweden and Spain in the medium, Greece, Portugal and France in the low — averaging the lowest of the high group, the two lowest of the medium and the lowest of the low, plus 3% for import cost, with the first generic at 80% of the originator. PPRI records central tendering, with larger tenders published in Tenders Electronic Daily.
What can Farbe Firma actually do for a partner supplying Cyprus?
Manufacture. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For an EU-facing partner we prepare CTD Module 3 quality documentation to EudraLex expectations, run ICH Q1A and Q1B stability, provide aseptic process simulation, container-closure integrity, sterility and LAL endotoxin data, and apply serialised 2D DataMatrix coding to Delegated Regulation 2016/161. We also prepare ACTD files for Asian markets.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments